Home » Posts tagged with » Dr. Albert Bourla
BNT162b2 Covid-19 vaccine candidate more than 90% effective in phase 3 trial, say Pfizer and BioNTech

BNT162b2 Covid-19 vaccine candidate more than 90% effective in phase 3 trial, say Pfizer and BioNTech

Pfizer and BioNTech announced that the BNT162b2 mRNA-based vaccine candidate has been shown to be more than 90% effective in the prevention of Covid-19 in participants of a phase 3 trial who were not previously exposed to the SARS-CoV-2 infection. The data is based on the first interim efficacy analysis from the phase 3 clinical […]

November 10, 2020No CommentRead More

FTC gives conditional approval to Mylan’s acquisition of Upjohn from Pfizer

October 31, 2020 No Comment
FTC gives conditional approval to Mylan’s acquisition of Upjohn from Pfizer

The US Federal Trade Commission (FTC) has granted conditional approval for Dutch pharma company Mylan’s acquisition of Upjohn, the off-patent branded and generic established medicines business of Pfizer. The deal was announced in July 2019 with an objective to create a new global pharma company through the merger of Mylan and Upjohn, which will be […]

Continue reading …

BNT162 COVID-19 vaccine candidate : US govt signs $2bn supply deal with Pfizer and BioNTech

July 22, 2020 No Comment
BNT162 COVID-19 vaccine candidate : US govt signs $2bn supply deal with Pfizer and BioNTech

Pfizer and BioNTech have bagged a $1.95 billion deal with the US government for supplying 100 million doses of their jointly developed BNT162 COVID-19 vaccine candidate. Recently, the two pharma companies were granted the fast track designation from the US Food and Drug Administration (FDA) for BNT162b1 and BNT162b1 vaccines, which are two of the […]

Continue reading …

Mylan Upjohn merger : Pfizer to merge off-patent drugs unit with Mylan

July 30, 2019 No Comment
Mylan Upjohn merger : Pfizer to merge off-patent drugs unit with Mylan

Mylan Upjohn merger : US pharma giant Pfizer will spin off Upjohn, its off-patent branded and generic established medicines business, and merge it with Dutch pharma company Mylan, to form a new global pharma company. As per the terms of the all-stock, Reverse Morris Trust transaction, each of Mylan shares will be converted into one […]

Continue reading …